FAP-1 loss impairs megakaryocyte demarcation membrane system and platelet function with myelofibrosis-like features.

Loss of FAP-1 causes defective megakaryocyte membrane development, impaired platelet function, and myelofibrosis-like features in mice, with 50% developing severe symptoms.

• Why it matters: Understanding the in vivo role of FAP-1 is crucial because its deficiency leads to platelet dysfunction and fibrosis, conditions relevant to human myelofibrosis and bleeding disorders.
• What they did: Researchers used FAP-1-deficient mice to analyze bone marrow, platelet function, and aging-related changes, revealing impaired DMS development, defective proplatelet formation, and Src-cofilin pathway disruption.
• The result: Findings show that FAP-1 loss causes megakaryocyte abnormalities and fibrosis-like features, which can be mitigated by Src inhibition, highlighting a potential therapeutic pathway for related human diseases.